Dasatinib, another FDA-approved PDGFR inhibitor, has also been shown to affect CAFs in lung cancer in vitro at nanomolar concentrations compared to other counterparts, including imatinib, nilotinib, and sorafenib[111]. The gene discussed is PDGFRB; the disease is lung carcinoma.